These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 27834341)
1. Zosteriform type in-transit metastasis of melanoma. Tas F Indian J Med Res; 2016 Jul; 144(1):143. PubMed ID: 27834341 [No Abstract] [Full Text] [Related]
2. NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. Perampaladas K; Hay N; Rinaldi F; Robertson J; Adam J Lancet Oncol; 2013 Jan; 14(1):20-1. PubMed ID: 23401870 [No Abstract] [Full Text] [Related]
3. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. Kim GH; Levy A; Compoginis G J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649 [TBL] [Abstract][Full Text] [Related]
4. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. Goldwirt L; Chami I; Feugeas JP; Pages C; Brunet-Possenti F; Allayous C; Baroudjian B; Madelaine I; Sauvageon H; Mourah S; Lebbé C Ann Oncol; 2016 Feb; 27(2):363-4. PubMed ID: 26578723 [No Abstract] [Full Text] [Related]
5. Reply to the letter to the editor 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance' by Funck-Brentano et al. Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Saiag P; Funck-Brentano C Ann Oncol; 2016 Feb; 27(2):364-5. PubMed ID: 26578725 [No Abstract] [Full Text] [Related]
6. Combined inhibition of BRAF and MEK in melanoma patients. Infante JR; Swanton C Lancet Oncol; 2014 Aug; 15(9):908-10. PubMed ID: 25037140 [No Abstract] [Full Text] [Related]
13. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Del Vecchio M; Ascierto PA; Mandalà M; Sileni VC; Maio M; Di Guardo L; Simeone E; Queirolo P Future Oncol; 2015; 11(9):1355-62. PubMed ID: 25952781 [TBL] [Abstract][Full Text] [Related]
14. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. Maleka A; Åström G; Byström P; Ullenhag GJ BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988 [TBL] [Abstract][Full Text] [Related]
15. Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases. Ribero S; Marra E; Tomasini CF; Fierro MT; Bombonato C; Longo C Br J Dermatol; 2017 Apr; 176(4):1101-1102. PubMed ID: 27515562 [No Abstract] [Full Text] [Related]
16. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma. Keating GM Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of mutated BRAF in melanoma. Kim T; Kim J; Lee MG N Engl J Med; 2010 Dec; 363(23):2261; author reply 2261-2. PubMed ID: 21121840 [No Abstract] [Full Text] [Related]
18. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494 [TBL] [Abstract][Full Text] [Related]
19. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Teuma C; Perier-Muzet M; Pelletier S; Nouvier M; Amini-Adl M; Dijoud F; Duru G; Thomas L; Fouque D; Laville M; Dalle S Cancer Chemother Pharmacol; 2016 Aug; 78(2):419-26. PubMed ID: 27371224 [TBL] [Abstract][Full Text] [Related]
20. When are signal transduction targeted therapies acting as immunotherapy? Flaherty KT Cancer Biol Ther; 2015; 16(5):645-7. PubMed ID: 25807058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]